An impact of Pten status on sensitivity to mTOR inhibitors has been observed in PTEN-deficient tumour cells and Pten-deficient MEFs, which were both more sensitive to mTOR inhibitors than corresponding Pten positive cells [23]. This evidence concerns the gene MTOR and neoplasm.